fluIT Biosystems

fluIT Biosystems GmbH operates as a specialized developer of advanced analytical systems for the life sciences sector, focusing on single-molecule detection. The company was established in 2006 as a spin-off from the Fraunhofer Institute for Applied Informationstechnik (FIT), leveraging technology developed within the institute. Dr. Sebastian Giehring served as the managing director during the company's formative years, from its founding until late 2010.

The firm's core offering is the ConSense™ Analyzer, an instrument that provides highly sensitive analysis of biomolecules down to picomolar concentrations. This system is built upon a proprietary and patented method known as accurate stochastic fluorescence spectroscopy (ASFS), which was developed at Fraunhofer FIT. The technology employs laser-induced fluorescence within microstructured chips to analyze signals from freely diffusing molecules, enabling applications such as the study of protein and antibody interactions and aggregation with minimal sample consumption. The business model centers on providing these analysis systems to customers in the life sciences industry, targeting applications in diagnostics and drug discovery where high sensitivity and rapid analysis are critical.

fluIT Biosystems is a venture capital-backed entity. It secured its initial seed funding from HighTech Gründerfonds in 2006. In June 2008, the company successfully closed a second financing round with a consortium of investors that included S-IFG, KfW Bankengruppe, HighTech Gründerfonds, and Rheinland Venture Capital, which has supported its development and marketing operations.

Keywords: single-molecule detection, life sciences analysis, confocal analysis systems, laser-induced fluorescence, protein interaction analysis, antibody aggregation, Fraunhofer spin-off, microfluidics, biomolecule analysis, ConSense Analyzer, ASFS, stochastic fluorescence spectroscopy, high-sensitivity diagnostics, drug discovery tools, biochemical assays, microstructured chips, picomolar concentration analysis, venture capital-backed, life science instrumentation, biophysical analysis